中药西药合用,切记15大禁忌 !

2016-05-18 佚名 药评中心

据统计,五分之三以上的中成药由西医师开具,中西药联用十分普遍。中西药配伍合理,可提高疗效,或减少毒副作用;配伍不合理,则会导致药效降低,或使毒副反应增加。总结中西药联用15大禁忌,供医师和药师参考。1药效相似的中西药合用1.中药麻黄、桂枝等解表发汗药,与扑热息痛、阿司匹林、布洛芬等解热镇痛药合用。●不良反应:发汗过多,引起虚脱;血液粘稠度增加,引起血压升高、心绞痛等。2.含麻黄的中成药,与洋地黄类

据统计,五分之三以上的中成药由西医师开具,中西药联用十分普遍。中西药配伍合理,可提高疗效,或减少毒副作用;配伍不合理,则会导致药效降低,或使毒副反应增加。总结中西药联用15大禁忌,供医师和药师参考。

1药效相似的中西药合用

1.中药麻黄、桂枝等解表发汗药,与扑热息痛、阿司匹林、布洛芬等解热镇痛药合用。

●不良反应:发汗过多,引起虚脱;血液粘稠度增加,引起血压升高、心绞痛等。

2.含麻黄的中成药,与洋地黄类强心甙如地高辛、西地兰等合用。

●不良反应:麻黄中所含的麻黄碱能加强心肌收缩力,增强强心甙的作用,引发心率失常。

3.含麻黄的中成药,不宜与氨茶碱同用。

●不良反应:有协同平喘作用,而毒性增加,可产生头痛、头昏、心率失常等,故合用时宜减少剂量。

4. 蟾酥、罗布麻、夹竹桃等含强心甙成分的中药,与洋地黄类强心甙合用。

●不良反应:易引发洋地黄中毒,应避免合用。

5.中药石决明、石膏、瓦楞子、龙骨、牡蛎等含钙离子的中药,与强心甙合用。

●不良反应:增加强心甙毒性。

6.六神丸、麝香保心丸、益心丸等中成药,与心律平、奎尼丁同服。

●不良反应:合用可使心跳骤停而发生危险。

7.含甘草次酸的中成药,如快胃片、补中益气丸、逍遥丸、香砂养胃丸、十全大补丸、人参当归丸、牛黄上清丸、安神补脑液、复方甘草合剂,以及具有肾上腺皮质激素样作用的中成药,如鹿茸等,与激素类、水杨酸类衍生物长期合用;与利尿酸、氢氯噻嗪等排钾利尿药联用;与洋地黄类强心甙合用。

●不良反应:均具有胃肠道刺激性,增加胃肠溃疡的发病率;与利尿药同用,容易诱发低血钾;与洋地黄类强心甙合用,能使体内钾离子浓度降低,导致心脏对强心甙的敏感性增高而引起中毒。

2药效相反的药物合用

8.含麻黄的中成药与催眠剂同用

●不良反应:有中枢兴奋作用的麻黄碱可减缓催眠药的作用。

9.含麻黄的中成药与氯丙嗪合用

●不良反应:可使血压下降过低。

10.含淀粉酶较多的六曲、麦芽组成的中成药(复方青黛丸、脑立清、小儿至宝丸等)与抗生素(尤其是口服抗生素)、水杨酸钠、阿司匹林、烟酸并用。

●不良反应:可降低淀粉酶的活性。如必须联用,至少要间隔2小时。

11.含甘草的中成药及含鹿茸的制剂(如健脑补肾丸、乳癖消、鹿胎膏、参茸安神丸等)与降血糖药胰岛素、格列本脲、苯乙双胍、甲苯磺丁脲等合用。

●不良反应:因前者可引起血糖上升,抵消降糖药的部分降糖作用,不利于糖尿病的治疗。

3合用会增加毒副作用的药物

12.含桃仁、苦杏仁、银杏、枇杷仁等组成的中成药,与麻醉药、镇静催眠药、止咳药如可待因、吗啡、杜冷丁、阿片制剂、苯巴比妥、利眠宁、安定等联用。

●不良反应:它们合用会引起呼吸中枢抑制甚至呼吸衰竭,并损害肝功能。合用时应注意,密切观察病情。

13.雷公藤与氯霉素长期合用。

●不良反应:两者都能抑制骨髓造血机能,可引起白细胞减少,产生血小板减少性紫癜。

14.含牛黄的中成药与苯巴比妥、吗啡、水合氯醛等中枢抑制药物合用。

●不良反应:因牛黄会增加对中枢的抑制作用,故西药应减量服用。

15.大活络丹、九分散、半夏露冲剂等含麻黄的中成药与呋喃唑酮、苯乙肼等单胺氧化酶抑制剂合用。

●不良反应:两者合用可能导致高血压危象和脑溢血。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=106626, encodeId=854f106626f0, content=深度好文,值得学习,赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Aug 29 07:54:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86668, encodeId=cb9a86668c6, content=这样的文章要多学, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20751724934, createdName=QQ76174b26, createdTime=Fri May 20 09:38:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545078, encodeId=d77d15450e8a9, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d9513684874, createdName=thinkibmz_44722598, createdTime=Fri May 20 02:17:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555610, encodeId=3b941555610ed, content=<a href='/topic/show?id=dcd89053994' target=_blank style='color:#2F92EE;'>#西药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90539, encryptionId=dcd89053994, topicName=西药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b4014636852, createdName=minzju5057, createdTime=Fri May 20 02:17:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86548, encodeId=72a286548b5, content=的确这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:39:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86546, encodeId=ec9d865464e, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:38:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86257, encodeId=a0328625e06, content=学习一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed May 18 14:59:00 CST 2016, time=2016-05-18, status=1, ipAttribution=)]
    2016-08-29 ylzr123

    深度好文,值得学习,赞!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=106626, encodeId=854f106626f0, content=深度好文,值得学习,赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Aug 29 07:54:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86668, encodeId=cb9a86668c6, content=这样的文章要多学, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20751724934, createdName=QQ76174b26, createdTime=Fri May 20 09:38:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545078, encodeId=d77d15450e8a9, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d9513684874, createdName=thinkibmz_44722598, createdTime=Fri May 20 02:17:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555610, encodeId=3b941555610ed, content=<a href='/topic/show?id=dcd89053994' target=_blank style='color:#2F92EE;'>#西药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90539, encryptionId=dcd89053994, topicName=西药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b4014636852, createdName=minzju5057, createdTime=Fri May 20 02:17:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86548, encodeId=72a286548b5, content=的确这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:39:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86546, encodeId=ec9d865464e, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:38:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86257, encodeId=a0328625e06, content=学习一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed May 18 14:59:00 CST 2016, time=2016-05-18, status=1, ipAttribution=)]
    2016-05-20 QQ76174b26

    这样的文章要多学

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=106626, encodeId=854f106626f0, content=深度好文,值得学习,赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Aug 29 07:54:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86668, encodeId=cb9a86668c6, content=这样的文章要多学, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20751724934, createdName=QQ76174b26, createdTime=Fri May 20 09:38:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545078, encodeId=d77d15450e8a9, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d9513684874, createdName=thinkibmz_44722598, createdTime=Fri May 20 02:17:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555610, encodeId=3b941555610ed, content=<a href='/topic/show?id=dcd89053994' target=_blank style='color:#2F92EE;'>#西药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90539, encryptionId=dcd89053994, topicName=西药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b4014636852, createdName=minzju5057, createdTime=Fri May 20 02:17:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86548, encodeId=72a286548b5, content=的确这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:39:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86546, encodeId=ec9d865464e, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:38:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86257, encodeId=a0328625e06, content=学习一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed May 18 14:59:00 CST 2016, time=2016-05-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=106626, encodeId=854f106626f0, content=深度好文,值得学习,赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Aug 29 07:54:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86668, encodeId=cb9a86668c6, content=这样的文章要多学, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20751724934, createdName=QQ76174b26, createdTime=Fri May 20 09:38:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545078, encodeId=d77d15450e8a9, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d9513684874, createdName=thinkibmz_44722598, createdTime=Fri May 20 02:17:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555610, encodeId=3b941555610ed, content=<a href='/topic/show?id=dcd89053994' target=_blank style='color:#2F92EE;'>#西药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90539, encryptionId=dcd89053994, topicName=西药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b4014636852, createdName=minzju5057, createdTime=Fri May 20 02:17:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86548, encodeId=72a286548b5, content=的确这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:39:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86546, encodeId=ec9d865464e, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:38:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86257, encodeId=a0328625e06, content=学习一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed May 18 14:59:00 CST 2016, time=2016-05-18, status=1, ipAttribution=)]
    2016-05-20 minzju5057
  5. [GetPortalCommentsPageByObjectIdResponse(id=106626, encodeId=854f106626f0, content=深度好文,值得学习,赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Aug 29 07:54:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86668, encodeId=cb9a86668c6, content=这样的文章要多学, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20751724934, createdName=QQ76174b26, createdTime=Fri May 20 09:38:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545078, encodeId=d77d15450e8a9, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d9513684874, createdName=thinkibmz_44722598, createdTime=Fri May 20 02:17:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555610, encodeId=3b941555610ed, content=<a href='/topic/show?id=dcd89053994' target=_blank style='color:#2F92EE;'>#西药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90539, encryptionId=dcd89053994, topicName=西药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b4014636852, createdName=minzju5057, createdTime=Fri May 20 02:17:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86548, encodeId=72a286548b5, content=的确这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:39:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86546, encodeId=ec9d865464e, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:38:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86257, encodeId=a0328625e06, content=学习一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed May 18 14:59:00 CST 2016, time=2016-05-18, status=1, ipAttribution=)]
    2016-05-19 milkshark

    的确这样

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=106626, encodeId=854f106626f0, content=深度好文,值得学习,赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Aug 29 07:54:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86668, encodeId=cb9a86668c6, content=这样的文章要多学, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20751724934, createdName=QQ76174b26, createdTime=Fri May 20 09:38:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545078, encodeId=d77d15450e8a9, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d9513684874, createdName=thinkibmz_44722598, createdTime=Fri May 20 02:17:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555610, encodeId=3b941555610ed, content=<a href='/topic/show?id=dcd89053994' target=_blank style='color:#2F92EE;'>#西药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90539, encryptionId=dcd89053994, topicName=西药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b4014636852, createdName=minzju5057, createdTime=Fri May 20 02:17:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86548, encodeId=72a286548b5, content=的确这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:39:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86546, encodeId=ec9d865464e, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:38:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86257, encodeId=a0328625e06, content=学习一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed May 18 14:59:00 CST 2016, time=2016-05-18, status=1, ipAttribution=)]
    2016-05-19 milkshark

    值得学习

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=106626, encodeId=854f106626f0, content=深度好文,值得学习,赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Aug 29 07:54:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86668, encodeId=cb9a86668c6, content=这样的文章要多学, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20751724934, createdName=QQ76174b26, createdTime=Fri May 20 09:38:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545078, encodeId=d77d15450e8a9, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d9513684874, createdName=thinkibmz_44722598, createdTime=Fri May 20 02:17:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555610, encodeId=3b941555610ed, content=<a href='/topic/show?id=dcd89053994' target=_blank style='color:#2F92EE;'>#西药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90539, encryptionId=dcd89053994, topicName=西药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b4014636852, createdName=minzju5057, createdTime=Fri May 20 02:17:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86548, encodeId=72a286548b5, content=的确这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:39:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86546, encodeId=ec9d865464e, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 07:38:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86257, encodeId=a0328625e06, content=学习一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed May 18 14:59:00 CST 2016, time=2016-05-18, status=1, ipAttribution=)]
    2016-05-18 1dd8c52fm63(暂无匿称)

    学习一下!

    0

相关资讯

王承德委员:越是有毒的中药越是好药

昨日的全国政协十二届四次会议医卫界别联组会议发言,全国政协委员、北京顺天德中医医院院长王承德的一番话,惊倒了会场上许多人。 说到现在中药制剂审批程序繁冗,王承德说,一个新制剂要进入临床应用,必须小白鼠点头才能通过,而中医药专家的话都不算数。他建议将中药制剂审批制度改为备案制,让更多的中医自制药用于普通患者。 “凡是药都有毒性,越是有毒的药越是好药。”王承德说,中医的毒性药治了许多西医治

今年由我国主导完成的ISO国际标准《中药编码规则》正式发布

近日,由我国主导的《中药编码系统——第一部分:中药编码规则》(ISO 18668-1)经过为期3个月的ISO最终国际标准草案投票,由国际标准化组织正式发布,标志着中药在数字化、标准化、信息化方面迈出了第一步。 该项目由深圳市卫生计生委副巡视员廖利平领衔申报,深圳市卫生计生委、深圳标准技术研究院、中国中医科学院等43个单位共77名专家,以及美国、加拿大、澳大利亚等20多个成员国的专家,历经了3

Sci Adv:中药黄芩能产生抗癌活性化合物

中科院上海生命科学研究院植物生理生态研究所、英国John Innes中心等机构的研究人员在四月八日的Science Advances杂志上发表文章,揭示了传统中药黄芩(Scutellaria baicalensis)生产抗癌化合物的分子机制。Fig. 1Specialized flavones found in S. baicalensis Georgi plant.

喜讯:继屠呦呦后,中医药又一世界大奖

5月2日,第20届未来健康技术峰会在麻省理工学院举办,西奈山医学院的华人教授李秀敏博士获颁“2016未来健康技术奖”,以表彰她在利用中草药治疗过敏和免疫系统疾病方面做出的杰出贡献。过敏性疾病越来越成为威胁人类生活质量的“隐形杀手”,尤其是在发达国家。据世界卫生组织统计,全世界有20%以上的人患有各类过敏性疾病,仅在美国就有约5000万人深受过敏之苦,目前尚无特效药从根本上解决问题。李秀敏教授长期从

四妙散为主方治疗痛风性关节炎疗效与安全性的系统评价

近期,河南中医学院第一附属医院研究人员发表论文,旨在评价四妙散为主方治疗痛风性关节炎的临床疗效及安全性。研究指出,四妙散为主方治疗痛风性关节炎的临床疗效及安全性较西药均有一定优势。由于纳入研究的方法学质量存在中度选择性偏倚的可能性,可能影响结果真实性,因此上述结论还有待开展更多高质量、大样本、随机双盲临床对照试验来验证。该文发表在2015年第13期《中国实验方剂学杂志》上。

国务院印发未来十五年中医药发展战略规划纲要

经李克强总理签批,国务院日前印发《中医药发展战略规划纲要(2016—2030年)》(以下简称《纲要》)。《纲要》明确了未来十五年我国中医药发展方向和工作重点,是新时期推进我国中医药事业发展的纲领性文件。 《纲要》提出,要坚持中西医并重,落实中医药与西医药的平等地位,遵循中医药发展规律,以推进继承创新为主题,以提高中医药发展水平为中心,以完善符合中医药特点的管理体制和政策机制为重点,以增进和维护人